Efficacy of medical plants on Vaginitis
Phase 3
- Conditions
- Vulvovaginal candidiasis.Vulvovaginal ulceration and inflammation in diseases classified elsewhere
- Registration Number
- IRCT2013012312250N1
- Lead Sponsor
- Ahvaz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Female
- Target Recruitment
- 70
Inclusion Criteria
Aged 20-30 years; clinical signs and symptoms of Candida vaginitis, pH vaginal (4-4.5) wet smear and culture positive. Exclusion criteria: Pregnant and lactating women; who have multiple sexual partners; diabetes; women with history of chronic Vulvar vaginal Candidiasis (at least 4 times in one year); use of immunosuppressive drugs; current use of oral combined contraceptive pills (OCPs); use of vaginal or oral anti-fungal in a month later and exposure of other Vaginitis.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Pruritus. Timepoint: Before treatment , 2 and 8 weeks after treatment. Method of measurement: Vsual Analog Scale for severty symptom.;Vaginal discharge. Timepoint: Before treatment , 2 and 8 weeks after treatment. Method of measurement: Visual Analog Scale for severty symptom-wet smear-culture.;Vulvar Erythematic. Timepoint: Before treatment , 2 and 8 weeks after treatment. Method of measurement: Visual Analog Scale for severty symptom-wet smear-culture.;Dysuria. Timepoint: Before treatment , 2 and 8 weeks after treatment. Method of measurement: Visual Analog Scale for severty symptom.;Vulvar Edema. Timepoint: Beftore treatment , 2 and 8 weeks after treatment. Method of measurement: Visual Analog Scale for severty symptom-wet test and cultuer.;Disparonia. Timepoint: Before treatment, 2 and 8 weeks after treatment. Method of measurement: Visual Analog Scale for severty symptom.
- Secondary Outcome Measures
Name Time Method